Type 2 diabetes

Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes worldwide. The number affected is increasing rapidly with alarming trends in children and young adults (up to age 40 years). Early detection and proactive management are crucial for prevention and mitigation o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The Lancet (British edition) Ročník 400; číslo 10365; s. 1803 - 1820
Hlavní autoři: Ahmad, Ehtasham, Lim, Soo, Lamptey, Roberta, Webb, David R, Davies, Melanie J
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Elsevier Ltd 19.11.2022
Elsevier Limited
Témata:
Adult
Age
Child
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - epidemiology
Epidemics
Glucose
Heterogeneity
Humans
Hyperglycemia
Insulin resistance
Metabolism
Microvasculature
Overweight
Pathophysiology
Patient-centered care
Pharmacogenetics
Pharmacogenomics
Precision Medicine
Quality of life
Technology
Trends
Weight control
Young Adult
Young adults
Africa
ISSN:0140-6736, 1474-547X, 1474-547X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes worldwide. The number affected is increasing rapidly with alarming trends in children and young adults (up to age 40 years). Early detection and proactive management are crucial for prevention and mitigation of microvascular and macrovascular complications and mortality burden. Access to novel therapies improves person-centred outcomes beyond glycaemic control. Precision medicine, including multiomics and pharmacogenomics, hold promise to enhance understanding of disease heterogeneity, leading to targeted therapies. Technology might improve outcomes, but its potential is yet to be realised. Despite advances, substantial barriers to changing the course of the epidemic remain. This Seminar offers a clinically focused review of the recent developments in type 2 diabetes care including controversies and future directions.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0140-6736
1474-547X
1474-547X
DOI:10.1016/S0140-6736(22)01655-5